We are live on ! Find out more
BCLI

BRAINSTORM CELL THERAPUTC
BCLI

Delisted

BCLI was delisted on the 17th of July, 2025.

Back to rankings

51 hedge funds and large institutions have $17.2M invested in BRAINSTORM CELL THERAPUTC in 2020 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 21 increasing their positions, 1 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

2,000% more repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 1

167% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 6

94% more capital invested

Capital invested by funds: $8.85M → $17.2M (+$8.36M)

19% more funds holding

Funds holding: 43 → 51 (+8)

4.35% more ownership

Funds ownership: 9.14% → 13.5% (+4.4%)

9% more call options, than puts

Call options by funds: $3.72M | Put options by funds: $3.41M

Holders
51
Holders Change
+8
Holders Change %
+18.6%
% of All Funds
1.12%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
16
Increased
21
Reduced
1
Closed
6
Calls
$3.72M
Puts
$3.41M
Net Calls
+$311K
Net Calls Change
+$1.44M

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$2.31M
2
Renaissance Technologies
Renaissance Technologies
New York
+$1.26M
3
BlackRock
BlackRock
New York
+$1.14M
4
Millennium Management
Millennium Management
New York
+$1.03M
5
EI
EAM Investors
California
+$676K

Top Sellers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$340K
2
Group One Trading
Group One Trading
Illinois
-$234K
3
Wolverine Trading
Wolverine Trading
Illinois
-$88K
4
Citadel Advisors
Citadel Advisors
Florida
-$63.7K
5
Commonwealth Equity Services
Commonwealth Equity Services
Massachusetts
-$50K

BCLI Hedge Fund Activity: Q1 2020 in Review

51 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in BRAINSTORM CELL THERAPUTC (BCLI) for Q1 2020, worth a combined $17.2M — up 94% from $8.85M a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new BCLI positions and 6 closed out — a net gain of 10 holders — while 21 added to existing stakes and 1 trimmed.

The largest buyer was Vanguard Group, adding an estimated $2.31M. The largest seller was Susquehanna International Group, exiting entirely with an estimated $340K sold.

  • 51 institutional investors held BRAINSTORM CELL THERAPUTC (BCLI) as of Q1 2020, up from 43 in Q4 2019.
  • Funds reported $17.2M of BRAINSTORM CELL THERAPUTC stock for Q1 2020, up 94% quarter-over-quarter.
  • 16 funds opened new BRAINSTORM CELL THERAPUTC positions in Q1 2020 and 6 closed out, a net change of +10 holders.
  • The largest BRAINSTORM CELL THERAPUTC buyer in Q1 2020 was Vanguard Group, an estimated $2.31M added.
  • The largest BRAINSTORM CELL THERAPUTC seller in Q1 2020 was Susquehanna International Group, an estimated $340K sold.

Based on aggregated 13F filings for Q1 2020.